The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr ...

CRISPR Therapeutics AG (CRSP) closed at $47.69 in the latest trading session, marking a -4.79% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 1.36%. Elsewhere ...

A vanadium MXene nanoparticle uses gene editing to strip tumors of heat resistance, then kills them with laser-triggered free ...

CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately. Shares have dropped 5% over the past week and are down 8% year-to-date, trading around $49.37 as of Tuesday morning. Piper Sandler, ...

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

Neither the Parties nor the Patent Trial and Appeal Board (PTAB) have been resting in addressing the decision by the Federal Circuit that vacated ...

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand treatment to others.

Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have developed a world-first portable point-of-care test that detects four common sexually transmitted ...